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A comparative characterization of 
the circulating miRNome in whole 
blood and serum of HCC patients
Devis pascut1, Helena Krmac2, Francesca Gilardi1, Riccardo patti3,4, Raffaella Calligaris2, 
Lory saveria Crocè1,3,4 & Claudio tiribelli  1
miRNAs are considered promising non-invasive biomarkers. serum represents the major source of 
biomarkers, being readily accessible for many analytical tests. Recently, whole blood has drawn 
increasing interest in biomarker studies due to the presence of cancer-interacting cells and circulating 
cancer cells. Although Hepatocellular Carcinoma (HCC) is the seventh most frequent cancer worldwide, 
fragmented information exists regarding the miRNome characterization in blood and serum. We 
profiled the circulatory miRNome of paired serum and blood samples from 20 HCC patients, identifying 
274 miRNA expressed in serum and 670 in blood, most of them still uncharacterized. 157 miRNA 
significantly differ between the two biofluids with 28 exclusively expressed in serum. Six miRNA clusters 
significantly characterize the two compartments, with the cluster containing miR-4484, miR-1281, 
miR-3178, miR-3613-3p, miR-4532, miR-4668-5p, miR-1825, miR-4487, miR-455-3p, miR-940 having 
the highest average expression in serum compared to blood. the ontological analysis revealed a role 
of these miRNAs in cancer progression, vascular invasion and cancer immune surveillance thought the 
regulation of DUSP1, PD-L1 and MUC1. Taken together, these results provide the most comprehensive 
contribution to date towards a complete miRNome profile of blood and serum for HCC patients. We 
show a consistent portion of circulatory miRNAs being still unknown.
Since their discovery in biofluids microRNAs (miRNAs) have drawn increasing interest in their use as circulatory 
biomarkers. These 21–23 short non-coding RNAs, responsible of the regulation gene expression in cells1, repre-
sent a class of promising non-invasive biomarker candidates as relatively stable to repeated freeze-thaw cycles, 
temperature and pH variations and prolonged storage2. More important, they are readily accessible in a wide 
range of biological samples, such as urine, saliva, blood, serum and other3.
Circulating miRNA profiles have been associated to different diseases4 but the most striking application 
regards several aspects of malignancies. Despite Hepatocellular Carcinoma (HCC) represents one of the most fre-
quent cancers worldwide, ranking as the second cause of cancer-related death5, a comprehensive characterization 
of the circulatory microRNA profiling is still missing. Actually 2588 mature human miRNAs are annotated on 
miRBase 21 (http://www.mirbase.org); however only a small fraction has been studied and characterized in HCC. 
Most of the investigations of miRNA as biomarkers consider serum or plasma as the most readily available and 
promising reservoir of miRNAs. Recently, whole blood have been considered as an alternative source of miRNAs6 
derived from blood cells such as neutrophils, monocytes, mature red blood cells7, regulatory T cells, recruited to 
the tumour site8, and cancer circulating cells. Since the role of these cells in cancer diseases, whole blood miRNAs 
became an attractive source of potential biomarkers during cancer pathogenesis.
Despite the increasing number of miRNA studies in HCC, a complete miRNome characterization of the bio-
fluids is missing. In this study we performed an expression profiling of 1733 circulating miRNA from paired 
whole blood and serum samples. We believe that the fully characterization of these two compartments may pro-
vide important information on the miRNA species that characterize the two biofluids with relevant implications 
in the interpretation of future cancer biomarker studies.
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Materials and Methods
patients. Twenty consecutive patients referring to the Liver Center between 2012 and 2017 with HCC accord-
ing to the EASL criteria were enrolled for the study. Samples were collected at the time of HCC diagnosis, before 
any oncological treatment. The clinical and demographic features of the groups are shown in Table S1.
All the patients provided written informed consent and patient anonymity has been preserved. Investigation 
was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by 
the regional ethical committee (Comitato Etico Regionale Unico FVG, No. 14/2012 ASUITS).
sample collection. Fasting paired whole blood and serum samples were collected at the same time from 
each patient during clinical visits. Peripheral blood (3 ml) was collected in Tempus™ Blood RNA Tube containing 
6 mL Stabilizing Reagent (Thermo Fischer Scientific, USA) and subsequently frozen at −80 °C for long-term stor-
age. Serum was collected in Vacuette® serum separating tubes (Greiner Bio-One GmbH, Austria). Samples were 
centrifuged at 3500 rpm for 10 minutes, aliquoted and stored at −80 °C until further use.
Assessment of hemolysis. The hemoglobin in serum was assessed with Beckman Coulter® DU®730 spec-
trophotometer using the Harboe Direct spectrophotometric method with Allen correction: Hb(g/l) = (167.2 × 
A415 − 83.6 × A380 − 83.6 × A450) × 1/1000 × 1/dilution in dH2O. The considered cut-off for serum was 0.020 g/L.
RNA isolation and quality assessment. Total RNA was isolated from Tempus™ Blood Tubes using the 
MagMAX™ for Stabilized Blood Tubes RNA Isolation Kit (Thermo Fischer Scientific, USA) following the man-
ufacturer protocol. Small RNAs, were isolated from 300 uL of serum using the miRCURY™ RNA Isolation Kits 
(Exiqon, Vedbaek Denmark) and quantified with the Qubit microRNA Assay Kit (Thermo Fischer Scientific, 
USA). The quality of the total RNA and miRNAs extracted was assessed with the Agilent RNA 6000 Nano Kit 
(agilent Technologies, USA) and Agilent Small RNA kit (Agilent Technologies, USA) respectively, by using the 
2100 Bioanalyzer Instrument (Agilent Technologies, USA). Samples with RIN less than 6 were discarded from 
the subsequent profiling experiments.
Microarray profiling. Small RNAs were extracted from whole blood and serum and independently profiled 
on the Affymetrix microRNA arrays containing 1,734 human mature miRNA probe sets. 130ng of RNA were 
labelled with the FlashTag™ Biotin HSR RNA Labeling Kit (Affymetrix®, Thermo Fischer Scientific, USA) and 
hybridized on Genechip miRNA 3.0 (Thermo Fischer Scientific, USA). Array cartridges were processed on an 
Affymetrix Fluidic Station 450 and scanned on an Affymetrix GeneChip 3000 7G. The robust Multichip Analysis 
(RMA) algorithm was used to derive CEL file probe-level hybridization intensities at the gene expression levels.
In silico data analysis. We search for the miRNA expression patterns in the miRmine database (http://
guanlab.ccmb.med.umich.edu/mirmine/index.html) that collects the expression profiles from different publicly 
available miRNA-seq datasets. Validated miRNA targets were downloaded from http://mirtarbase.mbc.nctu.edu.
tw/php/index.php. GOrilla (http://cbl-gorilla.cs.technion.ac.il), was used to determine pathway and GO terms 
enrichment of the miRNA validated targets. The search was relative to a background set of approximately 14,800 
human genes that could be associated with any miRNA from MiRTarBase. Enrichment results were visualized as 
“TreeMaps” generated in REViGO (http://revigo.irb.hr/). MiRNA target networks were built by using Tidyverse 
(version 1.2.1) and Igraph (version 1.1.2) packages in R environment (RStudio Team (2015). RStudio: Integrated 
Development for R. RStudio, Inc., Boston, MA (http://www.rstudio.com/). The StarBase v.3.0 database9, a 
Clip-Seq based miRNA expression dataset, generated by The Cancer Genome Atlas (TCGA) repository was used 
to search for differently expressed miRNAs in HCC tissues.
Data analysis and statistical methods. Gene expression differences between paired blood and serum 
were calculated with the Affymetrix transcriptome analysis console using paired one-way analysis of variance 
(ANOVA) test. Multiple testing correction was performed with the Benjamini-Hochberg method and false dis-
covery rate (FDR), corrected p-values were calculated. The relationship between expression levels of each miRNA 
within the family was analyzed using Pearson correlation. Correlation matrices were generated with R studio 
software by using and the Hmisc (version 4.1-1) Performance Analytics (version 1.4.3541) and Corrplot (version 
0.84) packages.
Results and Discussion
Profiling of total blood and serum identifies different patterns of microRNAs. We profiled the 
miRNome of 20 paired total blood and non-hemolized serum samples from HCC patients though the Affymetrix 
Genechip® mirna 3.0 array build on miRBase release 20.
According to the Absent/Present calling of the Affymetrix algorithm, we divided the circulatory miRNome in 
five quantiles based on their presence in the analyzed population. We considered the miRNAs in the first quantile 
as not expressed miRNAs, since they were detectable in less than five subjects. We found 1459 out of the 1734 
mature miRNA not expressed in serum, 99 were expressed in the 2nd quantile of the population (considered as 
rare miRNAs), 53 and 43 in the 3rd and 4th quantiles, respectively, and 79 in the 5th quantile (Table 1 ) .
In blood 1064 miRNAs were undetectable, 102 were in the 2nd quantile while 382 were present in the 5th 
quantile of the population (Table 1). Among the four quantiles of expressed miRNAs in the two biofluids, 28 
serum miRNAs were not expressed in blood, suggesting a pure extra-blood origin; most of them belong to the 2nd 
serum quantile representing the rarely detected miRNAs. MiR-4258, miR-3197 and miR-3162-3p are abundantly 
expressed only in serum of HCC patients. Seventeen miRNAs expressed in serum were rarely detected in blood 
(2nd blood quantile), while 1035 were undetectable in both biofluids. On the contrary, 424 miRNAs were uniquely 
detected in blood (Table 1).
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SERUM
2nd quantile 3rd quantile 4th quantile 5th quantile Not expressed
BLOOD
2nd 
quantile
miR-4490, miR-4423-3p, 
miR-4439, miR-297, 
miR-3152-3p, miR-4657, 
miR-200b-3p, miR-
2277-5p, miR-1972, 
miR-335-5p, miR-4797-
5p, miR-3927-3p
miR-4725-5p, miR-32-
5p, miR-548ai
mir-548aa none miR-100-3p, miR-101-3p, miR-1245b-3p, miR-1257, miR-1278, miR-1284, 
miR-1296-5p, miR-140-5p, miR-146b-3p, miR-154-5p, miR-188-3p, miR-
214-3p, miR-21-3p, miR-299-3p, miR-29b-3p, miR-29b-1-5p, miR-29c-3p, 
miR-301a-3p, miR-30b-3p, miR-30e-3p, miR-3129-5p, miR-3140-3p, 
miR-3146, miR-3150a-5p, miR-3151-5p, miR-3156-5p, miR-3173-5p, miR-
325, miR-338-5p, miR-34c-3p, miR-3607-5p, miR-3617-5p, miR-3622b-3p, 
miR-3650, miR-3667-3p, miR-3675-3p, miR-3689c, miR-370-3p, miR-373-
5p, miR-374a-5p, miR-374b-5p, miR-379-5p, miR-3918, miR-3925-5p, 
miR-3934-5p, miR-4257, miR-4266, miR-4272, miR-4294, miR-4326, 
miR-4428, miR-4434, miR-4435, miR-4444, miR-4465, miR-4478, miR-
4511, miR-4540, miR-4635, miR-4653-3p, miR-4659a-3p, miR-4660, miR-
4662a-3p, miR-4698, miR-4703-3p, miR-4705, miR-4720-3p, miR-4721, 
miR-4725-3p, miR-4763-5p, miR-4766-5p, miR-4774-5p, miR-4778-5p, 
miR-4795-5p, miR-485-5p, miR-493-5p, miR-509-3p, miR-548ab, miR-554, 
miR-557, miR-595, miR-598-3p, miR-616-5p, miR-623, miR-765, miR-922
3rd 
quantile
miR-3942-5p, miR-3128, 
miR-19a-3p, miR-
4717-3p, miR-4708-3p, 
miR-4445-3p, miR-548i, 
miR-603
miR-3910, miR-1323, 
miR-16-2-3p, miR-
4720-5p
miR-1272, 
miR-548z, 
miR-4474-
3p, miR-
628-5p
mir-940 let-7i-3p, miR-1-3p, miR-101-5p, miR-103a-2-5p, miR-1179, miR-1208, 
miR-1229-3p, miR-1244, miR-1273e, miR-1289, miR-130a-5p, miR-
1537-3p, miR-184, miR-1912, miR-193a-3p, miR-194-3p, miR-196b-5p, 
miR-221-5p, miR-22-5p, miR-23b-5p, miR-24-2-5p, miR-26b-3p, miR-27b-
5p, miR-296-3p, miR-219b-5p, miR-3064-3p, miR-3164, miR-3174, miR-
3180-3p, miR-32-3p, miR-330-3p, miR-3529-5p, miR-3651, miR-3688-3p, 
miR-3689b-3p, miR-3976, miR-4288, miR-4323, miR-433-3p, miR-4419b, 
miR-4422, miR-4442, miR-4448, miR-4455, miR-4461, miR-4472, miR-
4506, miR-4514, miR-451b, miR-4521, miR-4525, miR-4538, miR-4654, 
miR-4747-5p, miR-4748, miR-4755-5p, miR-4784, miR-4800-5p, miR-485-
3p, miR-497-5p, miR-500b-5p, miR-504-5p, miR-512-3p, miR-543, miR-
548ah-5p, miR-548k, miR-569, miR-640, miR-654-3p, miR-924, miR-96-5p
4th 
quantile
miR-664a-3p, miR-
3622a-3p, miR-143-3p, 
miR-551b-5p, miR-4440, 
miR-1255a
miR-642b-3p, miR-
4727-3p, miR-483-5p, 
miR-3201, miR-675-
3p, miR-2053, miR-
4742-5p
miR-
3157-3p, 
miR-191-3p, 
miR-1238-
3p, miR-
548aj-3p, 
miR-548ae-
3p, miR-
548 × -3p, 
miR-1246
miR-1184, miR-4706, 
miR-1263
miR-103b, miR-127-3p, miR-1287-5p, miR-129-2-3p, miR-1299, miR-134-
5p, miR-181d-5p, miR-1827, miR-186-5p, miR-188-5p, miR-192-3p, miR-
199a-3p, miR-199b-3p, miR-206, miR-208b-3p, miR-20b-3p, miR-21-5p, 
miR-2278, miR-3064-5p, miR-3136-5p, miR-3138, miR-3147, miR-3150b-
3p, miR-3157-5p, miR-3177-3p, miR-3179, miR-3192-5p, miR-326, miR-
330-5p, miR-34a-5p, miR-34b-3p, miR-3668, miR-3680-3p, miR-371a-5p, 
miR-382-5p, miR-3909, miR-3928-3p, miR-4309, miR-4312, miR-432-5p, 
miR-4321, miR-4419a, miR-4458, miR-4485-3p, miR-4498, miR-4499, 
miR-4526, miR-4535, miR-454-3p, miR-4646-5p, miR-4667-5p, miR-4672, 
miR-4685-5p, miR-4697-3p, miR-4723-5p, miR-4738-3p, miR-4753-5p, 
miR-4788, miR-4789-3p, miR-487b-3p, miR-502-5p, miR-514b-5p, miR-
542-5p, miR-556-3p, miR-576-5p, miR-616-3p, miR-624-5p, miR-641, 
miR-665, miR-671-3p, miR-7-5p, miR-7-1-3p, miR-769-3p, miR-874-3p, 
miR-942-5p
5th 
quantile
let-7a-5p, miR-1225-5p, 
miR-125b-5p, miR-
1273f, miR-1307-3p, 
miR-130a-3p, miR-
145-5p, miR-150-5p, 
miR-150-3p, miR-151a-
5p, miR-155-5p, miR-
15a-5p, miR-15b-5p, 
miR-181b-5p, miR-18a-
5p, miR-1909-5p, miR-
20b-5p, miR-222-3p, 
miR-23c, miR-26a-5p, 
miR-27a-3p, miR-29a-
3p, miR-30a-5p,miR-
3162-5p, miR-342-3p, 
miR-361-5p, miR-3648, 
miR-3679-5p, miR-378c, 
miR-378f, miR-378i, 
miR-3935, miR-4286, 
miR-4306, miR-4430, 
miR-4481, miR-4492, 
miR-4539, miR-4749-5p, 
miR-4791, miR-4800-3p, 
miR-486-3p, miR-491-
5p, miR-502-3p, miR-
503-5p, miR-532-5p, 
miR-550a-3p, miR-574-
5p, miR-629-3p, miR-
885-3p, miR-885-5p, 
miR-939-5p
let-7d-5p, let-7i-5p, 
miR-103a-3p, miR-
107, miR-1224-5p, 
miR-126-3p, miR-
1268b, miR-1275, miR-
130b-3p, miR-140-3p, 
miR-146a-5p, miR-17-
5p, miR-181a-5p, miR-
191-5p, miR-1910-5p, 
miR-193a-5p, miR-
197-3p, miR-20a-5p, 
miR-221-3p, miR-223-
3p, miR-23b-3p, miR-
24-3p, miR-30d-5p, 
miR-3124-5p, miR-
3135b, miR-320e, miR-
3621, miR-3646, miR-
371b-5p, miR-409-3p, 
miR-4253, miR-4459, 
miR-4486, miR-4741, 
miR-574-3p,
let-7c-5p, 
miR-
106a-5p, 
miR-106b-
5p, miR-
1207-5p, 
miR-1260a, 
miR-1260b, 
miR-1268a, 
miR-
151a-3p, 
miR-16-5p, 
miR-19b-3p, 
miR-22-3p, 
miR-23a-3p, 
miR-25-3p, 
miR-3141, 
miR-
378a-3p, 
miR-423-5p, 
miR-425-5p, 
miR-425-3p, 
miR-4433a-
3p, miR-
4454, miR-
4690-5p, 
miR-4739, 
miR-4758-
5p, miR-498, 
miR-584-5p, 
miR-92b-3p, 
miR-93-5p, 
miR-933
let-7b-5p, let-7b-3p, 
let-7f-1-3p, miR-122-5p, 
miR-1228-3p, miR-1228-
5p, miR-1280, miR-1281, 
miR-1469, miR-149-3p, 
miR-1587, miR-1825, 
miR-185-5p, miR-1908-5p, 
miR-1915-3p, miR-2861, 
miR-3178, miR-3185, 
miR-3196, miR-320a, miR-
320b, miR-320c, miR-320d, 
miR-3613-3p, miR-3613-5p, 
miR-3619-5p, miR-3656, 
miR-3665, miR-378h, 
miR-3921, miR-3940-5p, 
miR-3960, miR-4270, miR-
4274, miR-4281, miR-4310, 
miR-4429, miR-4443, miR-
4463, miR-4466, miR-4467, 
miR-4484, miR-4487, miR-
4488, miR-4497, miR-4505, 
miR-4507, miR-4508, miR-
451a, miR-4516, miR-4529-
3p, miR-4530, miR-4532, 
miR-455-3p, miR-4649-5p, 
miR-4651, miR-4668-5p, 
miR-4674, miR-4687-3p, 
miR-4689, miR-4695-5p, 
miR-4707-5p, miR-4710, 
miR-4734, miR-4745-5p, 
miR-4763-3p, miR-4787-5p, 
miR-486-5p, miR-548a-3p, 
miR-548ac, miR-638, miR-
663a, miR-762, miR-877-5p, 
miR-92a-3p
let-7d-3p, let-7e-5p, let-7f-5p, let-7g-5p, miR-100-5p, miR-106b-3p, miR-
1180-3p, miR-1202, miR-1226-3p, miR-1231, miR-1254, miR-1255b-5p, 
miR-125a-5p, miR-1270, miR-1271-5p, miR-1273c, miR-128-3p, miR-
1285-3p, miR-1292-5p, miR-1294, miR-129-5p, miR-1301-3p, miR-1303, 
miR-1304-5p, miR-1306-3p, miR-130b-5p, miR-132-3p, miR-139-5p, miR-
146b-5p, miR-148a-3p, miR-148b-3p, miR-151b, miR-152-3p, miR-17-3p, 
miR-181a-2-3p, miR-181c-5p, miR-182-5p, miR-183-5p, miR-183-3p, 
miR-185-3p, miR-18a-3p, miR-18b-5p, miR-1909-5p, miR-192-5p, miR-
194-5p, miR-195-5p, miR-1973, miR-1976, miR-199a-5p, miR-200c-3p, 
miR-202-3p, miR-210-3p, miR-2110, miR-2276-3p, miR-1281-3p, miR-
2392, miR-23a-5p, miR-25-5p, miR-26b-5p, miR-27b-3p, miR-28-3p, miR-
28-5p, miR-29b-2-5p, miR-29c-5p, miR-3074-5p, miR-30b-5p, miR-30c-5p, 
miR-30c-1-3p, miR-30e-5p, mir-31-5p, miR-3127-5p, miR-3129-3p, miR-
3130-5p, miR-3149, miR-3158-3p, miR-3158-5p, miR-3163, miR-3173-3p, 
miR-3180, miR-3187-3p, miR-3188, miR-3195, miR-3200-3p, miR-3200-
5p, miR-324-3p, miR-324-5p, miR-328-3p, miR-331-3p, miR-331-5p, 
miR-337-5p, miR-339-3p, miR-339-5p, miR-342-5p, miR-345-5p, miR-346, 
miR-3605-3p, miR-3605-5p, miR-3609, miR-361-3p, miR-3615, miR-
3619-3p, miR-3620-3p, miR-362-5p, miR-363-3p, miR-363-5p, miR-3652, 
miR-3667-5p, miR-3682-3p, miR-3691-5p, miR-378b, miR-378d, miR-378e, 
miR-378g, miR-378a-5p, miR-3911, miR-3936, miR-3937, miR-3940-3p, 
miR-3944-5p, miR-421, miR-422a, miR-423-3p, miR-424-3p, miR-4271, 
miR-4284, miR-4298, miR-4299, miR-4317, miR-4322, miR-4327, miR-
4436b-5p, miR-4447, miR-4462, miR-449b-3p, miR-4500, miR-4510, miR-
4513, miR-4534, miR-4634, miR-4640-5p, miR-4655-5p, miR-4656, miR-
4665-5p, miR-4669, miR-4676-5p, miR-4685-3p, miR-4688, miR-4695-3p, 
miR-4701-3p, miR-4708-5p, miR-4728-5p, miR-4732-3p, miR-4732-5p, 
miR-4736, miR-4743-5p, miR-4750-5p, miR-484, miR-494-3p, miR-500a-
5p, miR-500a-3p, miR-501-3p, miR-501-5p, miR-505-3p, miR-505-5p, 
miR-532-3p, miR-548q, miR-550a-5p, miR-550b-3p, miR-572, miR-575, 
miR-589-5p, miR-589-3p, miR-610, miR-625-5p, miR-628-3p, miR-629-5p, 
miR-636, miR-652-3p, miR-660-5p, miR-664a-5p, miR-671-5p, miR-720, 
miR-744-5p, miR-766-3p, miR-769-5p, miR-92b-5p, miR-93-3p, miR-941, 
miR-943, miR-98-5p, miR-99a-5p, miR-99b-5p
Not 
expressed
miR-202-5p, miR-
2116-3p, miR-3121-3p, 
miR-3153, miR-323b-3p, 
miR-337-3p, miR-
3663-3p, miR-3942-3p, 
miR-4290, miR-4646-3p, 
miR-4652-3p, miR-
4701-5p, miR-4722-3p, 
miR-4789-5p, miR-4793-
3p, miR-548u, miR-559, 
miR-570-3p, miR-602, 
miR-635, miR-877-3p
miR-1234-3p, miR-
4452, miR-450b-5p, 
miR-563.
miR-4258, 
miR-3197, 
miR-3162-3p
None
All the remaining
T a b le 1. MiRNA expression in blood and serum of HCC patients.
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Considering the miRNAs log2 average signal intensities the 5th serum group contains the miRNAs with the 
highest expression in serum and the higher expression compared to blood, with the exception of mir-486-5p, 
-92a-3p, -185-5p,-320d, -let7b-3p, -4429,- 451a; -4505, -4443, -4530, -1587, -877-5p, -4710. Mir-4689 has the 
same expression in both biofluids (Fig. 1a).
The serum 4th quantile has a more skewed distribution of the miRNA expression levels. The 50% of the miR-
NAs have a higher expression in blood, mir-let7c-5p, -106a-5p, -378-3p, -151a-3p and miR-584-5p have the high-
est blood expression compared to serum with 8.64 -14.16 (min-max) average expression in blood vs. 1.59-2.37 
(min-max) average expression in serum (Fig. 1b). MiR-4258, miR-3197 and miR-3162-3p were not detected in 
blood but have a high expression level in serum suggesting a pure extra-blood origin. Interestingly, very limited 
data existing link these miRNAs to cancer10,11. Mir-4258 was associated to chemo-resistant breast cancer cell 
lines and FFPE tissues10, while mir-3197 was up-regulated in colorectal liver metastases11. No or limited evidence 
exists about the expression of these miRNAs in HCC, offering new opportunities for future explorative studies 
in clinical specimens. Twelve out of fifty-three miRNAs have a higher expression in serum compared to blood in 
the third serum group. MiR-4452, -1234-3p, -563, and miR-450b-5p were undetectable in blood. In this group, 
29 miRNAs have an average log2 signal intensity less than 2. Mir-24-3p, -1234-3p, -3621, and miR-4720 -5p are 
the only miRNAs with an average log2 signal intensity greater than 2 and with the higher expression in serum 
(Fig. 2a).
The miRNAs in the 2nd quantile have the lowest average log2 signal intensities in serum. We defined them as 
rare miRNAs since they are present in less than the 40% of the screened population. Twenty-one of them were 
not expressed in blood. Mir-200b-3p, -297, -335-5p, -1972, -2277-5p, -3152-3p, -3927-3p, -4439, -4490, -4657, 
-4797-5p are also low expressed and rare miRNA in blood with the only exception of miR-2277-5p that has an 
average expression of 5.84 (Fig. 2b).
Fifty-two highly blood expressed miRNAs belonging to 5th blood quantile are also present in this group, with 
the exception of miR-23c, -1273f, -4791, that have a low average expression.
Differentially expressed miRNAs in whole blood and serum. We then compared the expression of the 
shared miRNA between the two biofluids, identifying 157 miRNA significantly differently expressed between total 
blood and serum (Anova p < 0.05). We filtered the miRNAs, identifying a total of 28 highly expressed miRNAs in 
serum, with a ≥10-fold higher levels compare to total blood, all belonging to the serum 5th quantile, except miR-
933, and miR-191-3p (Table S2). Among them, the liver specific miRNA miR-122-5p shows more than 348 fold 
increase in serum. Several other miRNAs were already associated to cancer, such as miR-455-3p12, -93313, -94014, 
including HCC13,15 in which miR-455-3p and miR-940 were downregulated in tumor liver tissue, compared to 
the surrounding disease13 or normal livers15, while mir-933 was upregulated13. To our knowledge, no evidence 
exists about their presence and clinical significance in serum of HCC patients. Regarding the recently discovered 
Figure 1. MiRNA average expression (log2) determined by miRNA microarray. The black bars correspond to 
the expression in serum while the grey ones correspond to the expression in whole blood. (a) MiRNA expressed 
in the 5th and (b) 4th serum quantile.
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miRNAs, the lack of experimental evidences linking them to cell pathways or specific diseases make difficult any 
speculation about their cell origin or clinical meaning.
Seventy-eight miRNAs have a ≥10-fold higher levels in blood than in serum. Among them, miR-150, -155, 
-223 were already known for their blood origin, being highly expressed in hematopoietic cells16 and mature blood 
cells. miR-223, together with miR-197, -574-3p and let-7a represent the previously identified myeloid miRNA 
signature7 with substantial differences in the expression between serum and total blood (Table S2). In addition, 
miR-150 is reported to be highly expressed in human lymphocytes7. Twenty-six miRNAs have ≤2 Fold of Change 
(FC) < 10 higher in total blood compared to serum, in this group the red blood cells (RBC) miR-451-3p; -92a-
3p, -16-5p, -486-5p7 are highly expressed in both compartments. In plasma hemolytic samples their expression 
increase with the extent of the hemolysis suggesting the high impact of RBC in the circulatory miRNA profile17. 
The differences in the average expression level in serum of the RBC-derived and white-cells-derived miRNAs 
suggest a significant contribution from the erythrocytes even in normal conditions (non-hemolyzed samples). 
Twenty-seven miRNAs, mostly belonging to the serum 5th quantile, have ≤2 FC < 10 higher expression in serum. 
Twenty-four miRNAs significantly differ with small changes in the two fluids (±1.1 ≤ FC < ±2). Sixty-three are 
expressed at comparable levels in both blood and serum.
Kirschner17 found a plasma miRNA signature influenced by hemolysis, including let7b-5p, miR-126-3p, -140-
3p, -15a-5p, -15b-5p, -16-5p, -20a-5p, -20b-5p, -320a, -425-5p, -486-3p, -140-3p, -451a. Those miRNAs are over-
expressed in blood compared to serum, furthermore miR-194-5p, -21-5p, -210-3p, -26b-5p, -324-3p, -331-5p, 
-454-3p, -484, -532-3p, 652-3p are exclusively found in blood in our samples. Interestingly, their suggested signa-
ture unaffected by haemolysis, including let-7a-5p, let7d-5p, miR-127-3p, -130b-3p, 143-3p, -146a-5p, -221-3p, 
-222-3p, -27b-3p, 324-5p, -338-5p, 339-5p, -744-5p is also overexpressed or exclusively expressed in our blood 
samples (Tables 1 and S2). Supporting our observations, Sangokoya18 reported that let7 family miRNAs 7a, 7b, 
7c, 7d, 7f are highly expressed in RBC since their role in reticulocytes. In our samples, miR-15b-5p, let-7a-5p 
and let-7d-5p have the highest blood expression with 5728, 4767 and 3824 fold of change compared to serum, 
respectively. These miRNAs increase even in presence of mild hemolysis in our samples (Fig. S1). The group of 
miRNAs unaffected by hemolysis (green cluster, Fig. S1), confirms only the previously identified miR-143-3p, 
while, hemolysis has a major effect on serum miR-130a-3p, -130b-3p, 15a-5p, -18a-5p, -30a-5p, -320e, -4506, 
-532-5p, -584-5p, included in the red cluster (Fig. S1).
Circulating miRNome cluster analysis. The unsupervised hierarchical clustering using Euclidean dis-
tances correlation measures of the intensities values for the set of blood and serum shared miRNAs showed 
the expected clustering of the cases indicating presence of blood and serum-specific miRNA expression profiles 
(Fig. 3).
Six distinguishable clusters were identified among the expressed miRNA. Cluster 1 (red) includes miRNAs 
with high expression level in blood, and the 50% of the serum samples have miRNA expressions comparable to 
blood. These RNAs include miR-486-5p, let-7b-5p, miR-92a-3p, miR-103a-3p, miR-107, miR-140-3p, miR-16-5p, 
miR-451a, miR-23a-3p, miR-17-5p, miR-191-3p, miR-25-3p, miR-425-5p, miR-93-5p. These miRNAs are widely 
and highly expressed among different human tissues (Fig. S2) and regulate key cellular pathways, such as cell 
Figure 2. MiRNA average expression (log2) determined by miRNA microarray. The black bars correspond to 
the expression in serum while the grey ones correspond to the expression in whole blood. (a) MiRNA expressed 
in the 3rd and (b) 2nd serum quantile.
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proliferation, cell death, kinase activities, aging, metabolic pathways, as evidenced by a validated target enrich-
ment analysis performed with GOrilla (Fig. S3 and Supporting File 1). Those miRNAs have been considered as 
circulating biomarkers for multiple diseases19 including HCC20. However, they are highly expressed in a wide 
range of tissues, including blood cells. Therefore blood must be considered as a source of these miRNAs in case of 
improper sample collection17, causing a misinterpretation of the results in biomarker discovery studies.
Figure 3. Heatmap with the pseudocolor scale underneath, of the differentially expressed miRNAs among the 
40 samples. Unsupervised hierarchical clustering is used to order samples and miRNAs, the log2-transformed 
microarray signal was considered. The sample tree with optimized leaf-ordering is drawn using Euclidean 
distances and average linkages for cluster-to-cluster distance. The six major clusters are identified by different 
colors: Cluster 1 (red), cluster 2 (blue), cluster 3 (green), cluster 4 (yellow), cluster 5 (orange), cluster 6 (light blue).
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Cluster 2 (blue) include miRNAs with high expression levels in blood and in some cases comparable expres-
sion in serum. This cluster includes a heterogenic profile of circulating miRNAs, involved in a wide variety of 
cellular pathways, some of them referring to blood-cells-related pathways: response to oxygen levels, regulation 
of kinase activity, regulation of immune system, hemopoiesis and regulation of apoptotic process (Fig. S4 and 
Supporting File 2).
Cluster 3 (green) includes the low expressed miRNAs in both serum and blood. Only four miRNAs of this 
cluster were previously studied: MiR-27a-3p, -29a-3p, -30a-5p, -143-3p. In HCC, miR-29a-3p, 30a-5p and 143-3p 
work as oncosuppressors21–23, while contrasting information exists about the oncogenic role of miR-27a, probably 
due to a different role of the two mature isoforms coming from the hairpin precursors24,25. Unfortunately, we were 
not able to identify the mature form studied in previous works in HCC.
Cluster 4,5 and 6 include miRNAs with higher expression in serum. The expression of miRNAs in Cluster 4 is 
highly variable, going from 5.89 FC of miR-2277-5p to 97 FC of miR-1228-3p. Very limited information regarding 
the cellular role of these miRNAs exist. MOAP1 (Modulator Of Apoptosis 1) and CSNK2A2 (Casein Kinase 2 
Alpha 2)26,27 are the only validated targets for miR-1228-3p, with opposite effects on cancer behavior, leading to a 
still questionable role of this miRNA in cancer.
To cluster 5 (orange) belong high expressed miRNAs in both biofluids, although there is a clear difference 
between the two compartments. Among the 21 members of the cluster only 6 miRNA have experimentally vali-
dated target genes on miRTarBase (http://mirtarbase.mbc.nctu.edu.tw), (miR-638; -663a; -762; -1908-5p; -4516; 
4674). The GO target enriched analysis evidenced the involvement of these miRNAs in key cell pathways such 
as cell cycle, cell migration, cell death regulation and drug response, often dysregulated in cancer (Fig. S5 and 
Supporting File 3). Since their high expression in both compartments, we hypothesize these miRNAs could rep-
resent a portion of miRNA widely released from body cells, although still missing information exists about tissue 
profiling on these miRNA (Fig. S6).
In cluster 6 (light blue), 10 miRNAs show high differences in the serum compared to blood samples, going 
from 68.61 FC, of miR-3613-3p, to 633.01 FC of miR-4484. To this cluster belong rather unknown miRNAs both 
in terms of function and clinical significance. The only validated targets listed in miRTarBase are DUSP1 (Dual 
Specificity Phosphatase 1) and CD274 for -miR-940 and MUC1 (Mucin 1) for miR-455-3p. Interestingly DUSP1 
and CD274, also known as B7H1 (B7 Homolog 1) or PD-L1 (PD-L1 - Programmed Cell Death 1 Ligand 1), are 
involved in cancer progression and vascular invasion28, and cancer immune surveillance29. The importance of 
these two targets was reported in two recent publications in which a relevant role of these two targets was discov-
ered in HCC30,31. DUSP1 was linked to HCC development and progression31, while the expression of PD-L1 in 
neoplastic or intra-tumoral inflammatory cells was related to tumor aggressiveness and response to treatments. 
Further evidence links the expression of miR-940 to a suppression of tumor invasion and migration32 and to 
apoptosis induction of cancer cells33. For the remaining miRNAs, only a weak experimental association to their 
putative targets exist.
Mirna families. MiRNA families are classified based on the mature miRNA sequence similarities and/
or structure of the miRNA precursor34. There have been evidences that miRNAs within the same fam-
ily have similar expression patterns and coordinately regulate cell biological processes35, ensuring robustness 
to gene regulatory networks36. In the present study, we further performed a global analysis of miRNA fami-
lies in the two biofluids of HCC patients, in order to identify potential functional correlations among miRNAs. 
Fifty-eight miRNA families are present in blood with at least two members. The top expressed families are the 
let-7/98/4458/4500, miR-378/422a/378bcdefhi, miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d, 
Figure 4. Mirna families in whole blood (black circles) and serum (grey circles). The area of the circle is 
proportional to the number of the family members expressed. The height correspond to the average log2 signal 
of the miRNA members within the family.
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miR-15abc/16/16abc/195/322/424/ 497/1907, miR-181abcd/4262, miR-25/32/92abc/363/363-3p/367 and the 
miR-320abcd/4429 family. Twenty-four families are entirely represented in blood (Table S3) including the top 
ranked miR-320abcd/4429 family.
In serum 214 miRNA families are present. The let-7/98/4458/4500, miR-320abcd/4429, miR-378/422a/378bc-
defhi and miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d families are the most represented families. Six 
families are fully represented in serum (Table S3) including the top ranked miR-320abcd/4429 family, as for blood.
MiRNA families are differently expressed in the two biofluids. The let-7 family and the miR-378 family are mostly 
expressed in blood, in which their expression is higher compared to serum (Fig. 4). Furthermore, there are some 
overlapping families between the two biofluids such as the miR-320 and the miR-548abakhjiwy families (Fig. 4).
In humans the let-7 family consist of 14 miRNA members, let-7a,b,c,d,e,f,g,i, miR-98, miR-4458 and miR-4500 
normally involved in hematopoietic stem progenitor cell homeostasis37. In cancers the expression is commonly 
down-regulated38. In HCC evidences of reduced let-7 family members was observed in tissues39,40. On the con-
trary, in serum those miRNA have been shown to be increased41. In our blood samples the let-7 family members 
are highly represented and have a high average expression (avg log2 expr. 10.35; min –max 8.87-15.27 for the let 
miRNAs, except for miR-4458 (avg log2 1.67; min-max 0.77-2.52) Table S3). The family members correlate in the 
expression in blood except miR-4458 that has the lowest correlation coefficient (Fig. 5a). The high correlation 
is also explained by the overlapping among validated mRNA targets (Fig. S7). This observation agrees with the 
important role of the family in the hematic cells and with the previous finding that reported those miRNA highly 
expressed in blood18. Interestingly, when comparing blood and serum, we observed no correlation in the expres-
sion among the blood and serum miRNAs (Fig. 5b), suggesting a possible extra-blood origin of the serum miR-
NAs. To notice that the overall correlation among the serum miRNA is generally lower than in blood (Fig. 5b).
Another highly correlated family in blood and serum is the miR-17 family. The family members miR-106a-5p, 
miR-106b-5p, miR-17-5p, miR-20b-5p, miR-93-5p are expressed in the two biofluids. However, while the expres-
sion in blood is homogeneous, more variability was observed in serum (Table S3 and Fig. 1, 2). Comparing the 
two biofluids, we found a negative correlation among serum miR-17-5p, -106b-5p, miR-93-5p and the miRNA 
family members in blood (Fig. 5c), suggesting two distinctive patterns for the two compartments. MiR-17-5p, 
-106b-5p, -93-5p have been extensively studied both in HCC tissues42 and serum43,44, in which they are consid-
ered as oncomirs. Thus, their expression in serum could be influenced by the disease rather than blood cells. 
The high and relatively stable expression of these miRNA suggests a physiological role in blood cell. A high and 
stable expression of the miR-320 family was observed in blood. Moreover, a high intra-blood and intra-serum 
exist among the miR-320a, miR-320b and miR-320c members, probably due to the high conservation among 
Figure 5. (a) Correlation chart of the let7 family members in whole blood. Correlation chart of the let7 family 
(b), miR-17 family (c), and miR-320 family members (d) in both whole blood and serum. The upper-right 
side shows the correlation coefficient and p-value for each pairwise correlation. The lower-left side show the 
distribution. b,c and d show the correlation for the miRNA that are expressed in both biofluids. Intra-blood 
correlations (black quadrants) and intra-serum correlations (grey quadrants) are reported. Outside the 
quadrants the pairwise inter-biofluids correlations.
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the sequences (Fig. 5d). Although the very similar pattern, there is no significant correlation between the two 
biofluids for the three miRNAs. Only a slightly positive association was observed among serum miR-4429 and 
the blood miR-320a,b,c.
To the miR-378 family belong miR-378a,b,c,d,e,f,h,I and miR-422 all expressed in blood, while in serum only 
miR-378a,c,h,I are detectable (Table S3). MiR-378a has been reported to be involved in cell survival, tumor growth 
and angiogenesis45. In liver it inhibits the hepatic stellate cell activation46 and works as an onco-suppressor by tar-
geting VEGFR, PDGFRβ and c-Raf47. Very few information exist about the other family members, despite their 
high expression in blood (miR-378c,d,f,i) and serum (miR-378h). MiR-378h has a 47.02 fold higher expression in 
serum compared to blood (Table S2), however, to our knowledge no information about this miRNA is available in 
literature. Interestingly miR-378h was previously detected only in liver and testis (Fig. S8). The weakly associated 
target genes, downloaded from MirTarBase, link this miRNA to FAS signaling pathway, VEGF signaling pathway, 
Insulin/IGF pathway-protein kinase B signaling cascade, p53 pathway feedback loops 2, Oxidative stress response, 
Gonadotropin-releasing hormone receptor pathway, Angiogenesis, although no statistically enrichment was 
obtained (Table S4). To further clarify the function of this miRNA in HCC more extensively studies are needed.
MiRNA differently expressed in HCC. To further verify the consistency of our data with previously iden-
tified miRNA HCC, we searched in StarBase v.3.0 database for differently expressed miRNAs in 370 HCC com-
pared to 50 normal livers. Among the 187 miRNAs expressed in the serum of our patients, we identified 139 
being already identified in HCC tissues, however only 95 with a log2(RPM + 0.01) > 0.1 (Table S5). Twenty-five 
miRNAs were significantly up-regulated in HCC tissues compared to normal liver, while 40 were significantly 
downregulated (Table S5). With this preliminary study we are not able to define a clinical significance for these 
findings that should be further validated in independent translational studies.
Conclusions
In recent years, circulating biomarkers have been considered as a powerful, non-invasive tool for disease detec-
tion or cancers follow-up. MiRNAs are eligible biomarker candidates for their stability, easy assessment and role 
in gene regulation. Although detectable in all biofluids, serum is the most studied source as readily accessible as 
fresh or frozen material. A portion of cell-free circulating miRNAs released in serum could originate from can-
cerous cells during tumour progression being promising candidates as cancer biomarkers.
Recently, an increasing interest is paid in the study of the whole blood miRNome6,48 originating from mono-
cytes, platelets, mature red blood cells7, cells involved in cancer immune-surveillance8 and circulating cancer 
cells. Giving the systemic nature of cancer, the whole blood miRNome could represent an important source of 
information for biomarker discovery studies. In this work we compared the circulating miRNome from two dis-
tinct compartments: Whole blood and serum. Despite the multitude of circulatory miRNAs investigations being 
present in literature, still fragmented and scanty information exists on HCC. We identified different expression 
patterns for the two biofluids. Some miRNAs, previously identified as serum biomarkers in HCC are also highly 
expressed in blood, such as miR-107, miR-92a-3p20, miR-17-5p, miR-22344. On the other hand, the role and 
clinical significance of some highly expressed miRNAs in serum are still unexplored in HCC, such as miR-4484, 
miR-940, miR-933, miR-378h, providing hints for new researches in this field. Despite the major limitation of our 
study consisting in the relatively low number of patients, we believe that this study might represent a step in the 
way for future studies enrolling larger cohorts for an independent validation. Our contribution in the character-
ization of the circulating miRNome in blood and serum from HCC patients is still exploratory and clinical and 
functional studies are desired to further promote the use of miRNAs as biomarkers in a clinical setting.
Data Availability
The datasets used during the current study are available from the corresponding author on reasonable request.
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